Xconomy

OCTOBER 7, 2016

. —Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. The funding could be as much as $100 million, and the first grants will be announced in 2017. —The U.S. —The U.S.

Technical Review 77

Technical Review Study Layoffs San Diego 77

Xconomy

JULY 15, 2016

After last week’s revelation of three patient deaths in its leading cancer immunotherapy trial, the FDA suspended the study. CEO Jeff Jonas told Xconomy previously that positive results could encourage Sage to dive deeper into studying mood disorders—from panic attacks to post-traumatic stress disorder. —With $1.25

News 40

News Technical Review San Diego Startup 40

Xconomy

JUNE 17, 2016

. —All the while, Merck (NYSE: MRK ) disclosed pembrolizumab (Keytruda) bested chemotherapy in a Phase 3 trial of previously untreated patients with non-small cell lung cancer; the study was stopped early because of the positive results. —Ben Fidler contributed to this report. Reprints | Share:

News 55

News Technical Review Conference Report 55

Xconomy

JANUARY 25, 2019

In a week of big personnel moves, none was more surprising than Editas Medicine CEO Katrine Bosley’s departure.

Guide 63

Guide Patents Startup Develop 63

Xconomy

JUNE 30, 2017

There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.

Writing 56

Writing Report Artificial Inteligence San Diego 56